Skin cancer kills by spreading from the skin to vital organs, most commonly the lungs, liver, and brain. Once cancer cells reach these organs, they disrupt normal function, trigger widespread inflammation, and gradually overwhelm the body’s ability to sustain itself. The specific path to death depends on which type of skin cancer is involved and where it spreads.
Melanoma: The Most Lethal Type
Melanoma accounts for the majority of skin cancer deaths because of its strong tendency to metastasize, meaning it sends cancer cells through the bloodstream or lymphatic system to distant parts of the body. When caught early and still confined to the skin, melanoma has a 97.6% five-year survival rate. Once it reaches distant organs, that number drops to 16.2%.
The organs melanoma targets most frequently are the lungs, liver, bones, and brain. Each site creates its own set of life-threatening problems. Lung metastases can fill the airways or surrounding tissue with tumor growth, making it progressively harder to breathe. Liver metastases interfere with the organ’s ability to filter toxins and produce essential proteins, eventually leading to organ failure. Bone metastases weaken the skeleton and can cause dangerous spikes in blood calcium levels, which disrupt heart rhythm and kidney function.
How Brain Metastases Cause Death
The brain is one of melanoma’s most dangerous destinations. Tumors growing inside the skull create pressure because the brain has no room to expand. This pressure causes headaches, seizures, loss of movement in the arms or legs, and increasing drowsiness, which is the most common symptom in end-stage brain metastases. In some cases, brain metastases trigger a stroke by disrupting blood vessels. As tumors grow, the swelling and pressure can compress the brainstem, which controls breathing and heart rate, and this is often the final event.
How Non-Melanoma Skin Cancers Kill
Basal cell carcinoma and squamous cell carcinoma are far less deadly than melanoma, but they still cause an estimated 2,000 to 8,000 deaths per year in the United States. The two types kill through different mechanisms.
Squamous cell carcinoma is responsible for most non-melanoma skin cancer deaths because it can metastasize, particularly to nearby lymph nodes and then to distant organs. People with suppressed immune systems, such as organ transplant recipients or those being treated for autoimmune diseases like lupus, face a significantly higher risk of squamous cell carcinoma spreading and becoming fatal.
Basal cell carcinoma almost never metastasizes. Instead, it kills through local invasion. Left untreated, a basal cell tumor on the scalp or face can slowly erode through skin, bone, and even the skull itself. In extremely rare cases, this invasion reaches the protective membranes around the brain (the meninges) or the brain tissue, causing compression, infection, or hemorrhage. Most people who die from basal or squamous cell cancers are older adults who delayed seeking medical care until the tumor had grown very large.
Cachexia: The Wasting That Weakens the Body
Advanced skin cancer, like other late-stage cancers, can trigger a syndrome called cachexia. This is a severe wasting condition where the body breaks down its own muscle and fat far faster than they can be replenished. It occurs in up to 80% of people with advanced cancer and is thought to directly cause up to 30% of all cancer deaths.
Cachexia isn’t simply weight loss from not eating enough. It’s driven by widespread inflammation that the cancer itself provokes. Tumors and immune cells release chemical messengers called cytokines that disrupt how the body processes energy. Muscles wither even if someone is eating. Appetite drops further, robbing the body of fuel. The heart is a muscle too, so as cachexia progresses, it can lead to heart failure or respiratory failure as the muscles needed for breathing weaken. A loss of 5% or more of body weight over six months, combined with fatigue and reduced strength, is the clinical threshold.
Immune Suppression and Infection
Advanced skin cancer and its treatments can both weaken the immune system, leaving the body vulnerable to infections it would normally fight off easily. Cancer cells consume resources and disrupt the bone marrow’s ability to produce healthy immune cells. Treatments like chemotherapy and newer immunotherapies add further stress. Pneumonia, sepsis, and other infections become serious threats. Research from Karolinska Institutet has shown that proactively managing infections could improve survival, since both the disease and its treatments compound the immune deficit.
How Treatment Has Changed the Picture
Modern immunotherapy drugs have dramatically improved survival for advanced melanoma, but they haven’t eliminated mortality. In a study of nearly 2,000 melanoma patients treated with checkpoint inhibitor immunotherapy, 15% died within the first 12 weeks of treatment. The overwhelming majority of those early deaths (92%) were caused by the melanoma itself continuing to progress despite treatment.
A small but real fraction of deaths, about 5%, resulted from the treatment’s own toxicity. Immunotherapy works by releasing the brakes on the immune system, but that unleashed immune response can sometimes attack the patient’s own heart, lungs, or liver. The most common fatal side effects were damage to the heart and lungs. These treatment-related deaths were more common in elderly patients, with an average age of 74, and most occurred after just the first dose. For the majority of patients, though, immunotherapy has transformed stage IV melanoma from a near-certain death sentence into a condition where a meaningful percentage achieve long-term remission.
What Determines Whether Skin Cancer Becomes Fatal
Two factors matter most: how deep the tumor has grown into the skin and whether it has ulcerated (broken through the skin surface to form an open sore). Melanomas thicker than 4 millimeters carry the highest risk. Ulceration at any thickness signals a more aggressive tumor. Stage at diagnosis is the single strongest predictor of survival. A melanoma caught while still in the outermost layer of skin has a 100% five-year survival rate. One that has already spread to distant organs drops to 16.2%.
This gap between early and late detection is why skin cancer’s lethality is so tied to timing. The cancer itself doesn’t change its biology based on when it’s found, but the body’s ability to survive it depends almost entirely on how far it has traveled before treatment begins.